<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id>
<journal-title-group>
<journal-title>Dialogues in Clinical Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1294-8322</issn>
<issn pub-type="epub">1958-5969</issn>
<publisher>
<publisher-name>Les Laboratoires Servier</publisher-name>
<publisher-loc>France</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31636489</article-id>
<article-id pub-id-type="pmc">6787545</article-id>
<article-id pub-id-type="doi">10.31887/DCNS.2019.21.2/dbertrand</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Receptor variants and the development of centrally
acting medications </article-title>
<trans-title-group xml:lang="es">
<trans-title>Variantes de receptores y el desarrollo de medicamentos de acción central.</trans-title>
</trans-title-group>
<trans-title-group xml:lang="fr">
<trans-title>L’importance des organismes de recherche sous contrats dans le développement de composés agissant sur le système nerveux</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Neale</surname>
<given-names>Stuart A.</given-names>
</name>
<degrees>PhD</degrees>
<aff>Neurexpert Limited, The Core, Science Central,
Newcastle Upon Tyne, UK </aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kambara</surname>
<given-names>Kumiko</given-names>
</name>
<degrees>PhD</degrees>
<aff>HiQScreen Sàrl, Geneva, Switzerland</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Salt</surname>
<given-names>Thomas E.</given-names>
</name>
<degrees>PhD</degrees>
<aff>Neurexpert Limited, The Core, Science Central,
Newcastle Upon Tyne, UK; Honorary Professor,
University of Newcastle, Newcastle, UK</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bertrand</surname>
<given-names>Daniel</given-names>
</name>
<degrees>PhD</degrees>
<aff>HiQScreen Sàrl,
Geneva, Switzerland; Emeritus Professor,
Medical Faculty, Geneva, Switzerland.</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="COR1">HiQScreen Sàrl, 6, rte de Compois, 1222 Vésenaz, Geneva,
Switzerland.<label>*</label> E-mail:
<email>daniel.bertrand@hiqscreen.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<issue>2</issue>
<fpage>149</fpage>
<lpage>157</lpage>
<permissions>
<copyright-statement>© 2019, AICH – Servier Group﻿Copyright © 2019 AICH – Servier
Group. All rights reserved</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
<license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which
permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>The progressive changes in research paradigms observed in the largest
pharmaceutical companies and the burgeoning of biotechnology startups over the
last 10 years have generated a need for outsourcing research facilities. In
parallel, progress made in the fields of genomics, protein expression in
recombinant systems, and electrophysiological recording methods have offered new
possibilities for the development of contract research organizations (CROs).
Successful partnering between pharmaceutical companies and CROs largely depends
upon the competences and scientific quality on offer for the discovery of novel
active molecules and targets. Thus, it is critical to review the knowledge in
the field of neuroscience research, how genetic approaches are augmenting our
knowledge, and how they can be applied in the translation from the
identification of potential molecules up to the first clinical trials. Taking
these together, it is apparent that CROs have an important role to play in the
neuroscience of drug discovery. </p>
</abstract>
<trans-abstract xml:lang="es">
<p>Los cambios progresivos en los paradigmas de investigación observados en las principales compañías farmacéuticas y el desarrollo de las nuevas empresas de biotecnología en los últimos 10 años han generado la necesidad de subcontratar las instalaciones de investigación. Paralelamente, el progreso realizado en los campos de la genómica, la expresión de proteínas en sistemas recombinantes y en los métodos de registro electrofisiológico han ofrecido nuevas posibilidades para el desarrollo de organizaciones de investigación por contrato (OIC). La asociación exitosa entre las compañías farmacéuticas y las OIC depende en gran medida de las competencias y la calidad científica que se ofrecen para el descubrimiento de nuevas moléculas activas y sitios de acción. Por lo tanto, es fundamental revisar el conocimiento en el campo de la investigación en neurociencia, cómo las aproximaciones genéticas están aumentando nuestro conocimiento y cómo se pueden aplicar en la traducción desde la identificación de potenciales moléculas hasta los ensayos clínicos iniciales. Tomando esto en conjunto, es evidente que las OIC tienen un papel importante que desempeñar en la neurociencia del descubrimiento de fármacos.</p>
</trans-abstract>
<trans-abstract xml:lang="fr">
<p>Les modifications observées durant les dix dernières années concernant les modèles organisationnels des grandes industries pharmaceutiques ainsi que la multiplication des entreprises de biotechnologies ont augmentés les besoins de recherches dans des laboratoires privés. En parallèle les progrès en génomique ainsi que dans les systèmes d’expression de protéines recombinantes ont ouvert de nouvelles possibilités pour le développement d’unités indépendantes qui offrent de la recherche sous contrats (CRO).
Le succès des recherches distribuées entre partenaires pharmaceutiques et les unités de recherche privées dépend essentiellement des compétences ainsi que des qualités scientifiques qui peuvent être offertes pour la découverte de nouvelles molécules agissant sur une cible définie. Il est important d’examiner, comment les nouvelles découvertes effectuées dans le domaine de la génétique et l’accroissement de nos connaissances, peuvent se traduire dans l’identification de nouvelles molécules à visée thérapeutiques depuis la recherche fondamentale jusqu’aux essais cliniques. D’une manière globale, il apparaît que les unités de recherche contractuelles ont un rôle majeur à jouer dans le domaine de la recherche en neuroscience ainsi que dans la découverte de nouveaux principes actifs. 
</p>
</trans-abstract>
<kwd-group>
<kwd>
<italic>drug discovery</italic>
</kwd>
<kwd>
<italic>central nervous system</italic>
</kwd>
<kwd>
<italic>contract research organization</italic>
</kwd>
<kwd>
<italic>electrophysiology</italic>
</kwd>
<kwd>
<italic>pharmacology</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>Introduction </title>
<p>
Analysis of the global burden of disease reveals that neuropsychiatric
disorders (documented worldwide in 21 regions, which were subsequently divided into
195 countries) represent the largest cause of disability-adjusted life-years and are
ranked second after the cardiovascular diseases. <sup><xref ref-type="bibr" rid="ref1">1</xref></sup>
With a prevalence of about 1%, schizophrenia represents a major
burden, both in terms of suffering and economic impact. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
  </p>
<p>
The World Health Organization estimates that depression is affecting as
much as 4.4% of the global population, that 3.6% are suffering from anxiety
disorder, and that the population of Alzheimer disease-affected patients is expected
to grow from about 4% to 17% between 2020 and 2025. Fighting neuropsychiatric
disorders therefore represents one of the many challenges in today’s medical care.  </p>
<p>
The initial discovery made serendipitously in the 1950s of centrally
acting compounds such as, for example, the benzodiazepines, and the observation that
these molecules are active at the g-aminobutyric acid (GABA) ionotropic receptors
(GABA <sub>A</sub>
<sup><xref ref-type="bibr" rid="ref3">3</xref></sup>
) soon allowed the identification of newer molecules acting on
GABAergic systems. Similarly, the first antipsychotic, chlorpromazine, which marked
a turning point in the history of psychiatry, was subsequently found to act at the
dopamine D <sub>2</sub>
receptors. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup>
, <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>
Additional experiments revealed, however, that this molecule probably
acts at many different targets ranging from G-coupled proteins such as the histamine
receptors <sup><xref ref-type="bibr" rid="ref6">6</xref></sup>
to ligand gated ion channels such as the neuronal nicotinic
acetylcholine receptors (nAChRs, <sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
- <sup><xref ref-type="bibr" rid="ref9">9</xref></sup>
) or the glutamatergic N-methyl-D-aspartate (NMDA)receptors. <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>
, <sup><xref ref-type="bibr" rid="ref11">11</xref></sup>
  </p>
<p>
Progress made in the understanding of the central nervous system has
led to deeper investigations of the brain’s precise circuitry. Decisive advances
have been achieved in the elucidation of the mechanisms at play in the hippocampus
related to cognitive processes such as learning and memory. <sup><xref ref-type="bibr" rid="ref12">12</xref></sup>
However, in spite of our current understanding of brain function,
translation from animal models to human pathophysiology is still insufficient to
overcome the barriers seen in the development of new active compounds.  </p>
<p>
Difficulties in drug discovery are illustrated in the field of nAChRs,
with the latest failure in a phase III clinical trial conducted with encenicline,
which had shown positive outcomes both in animal models <sup><xref ref-type="bibr" rid="ref13">13</xref></sup>
and in clinical phase II. <sup><xref ref-type="bibr" rid="ref14">14</xref></sup>
That is, this quinuclidine derivative was found to be a powerful
agonist at the human a7 nAChR displaying a large safety margin and proving
efficacious in different animal models. <sup><xref ref-type="bibr" rid="ref15">15</xref></sup>
Although encenicline had shown improvements in cognitive impairments
in schizophrenic patients versus placebo in the early clinical phase II, <sup><xref ref-type="bibr" rid="ref14">14</xref></sup>
administration of this compound to a larger population of
schizophrenic patients did not yield significant improvements over the current
treatments. Combined with the lack of success of other nAChR-specific molecules this
caused a halt of the research in this particular field. <sup><xref ref-type="bibr" rid="ref16">16</xref></sup>
Similar situations have been seen for clinical trials for other
central nervous system (CNS) disorders, such as fragile X syndrome, where the
disruption in synaptic transmission believed to underlie the condition appeared to
be well characterized preclinically, but in clinical trials molecules targeting
G-protein coupled receptors (GPCRs) failed to show efficacy. <sup><xref ref-type="bibr" rid="ref17">17</xref></sup>
While it would go beyond the scope of this paper to review the
multiple failures of compounds acting at a specific target, it is instructive to
analyze how studies were designed and conducted and the intrinsic difficulties in
targeting compounds for the CNS; instead, our focus here is on preclinical work and
how a more in-depth understanding of the neurobiology that can be provided by
specialist contractors may lead to future success.  </p>
</sec>
<sec>
<title>From gene to function </title>
<p>
Novel approaches in drug discovery encompass knowledge obtained from
large genomic databases and correlations observed between genes and diseases. A good
example was the identification of variants in the nicotinic receptor gene
<italic>CHRNA5</italic>
and risk of tobacco-smoking dependence. <sup><xref ref-type="bibr" rid="ref18">18</xref></sup>
This was further reinforced in different studies which also unveiled
the broad interactions between multiple factors ranging from the gene promotor,
cis-regulatory elements of gene expression, or multiple gene interactions. <sup><xref ref-type="bibr" rid="ref19">19</xref></sup>
- <sup><xref ref-type="bibr" rid="ref21">21</xref></sup>
Another example was the association between mutations in the g2
subunit of GABA <sub>A</sub>
receptor and a spectrum of epilepsy syndromes ranging from absence
epilepsy to Dravet syndrome that provided a good starting point to identify the
mechanisms underlying these pathologies. <sup><xref ref-type="bibr" rid="ref22">22</xref></sup>
To examine if and how compounds specifically targeting the GABA
<sub>A</sub>
receptors would prove beneficial it is first necessary to revisit our
knowledge concerning these receptors.  </p>
<p>
In the case of the GABA <sub>A</sub>
receptors, 19 genes encoding these proteins have been identified and
their chromosome location determined. A single receptor results from the assembly of
five subunits around an axis of symmetry formed by the ionic pore through which
chloride anions will flow upon stimulation by the agonist. Depending on the chloride
gradient, activation of GABA <sub>A</sub>
receptors can yield either a hyperpolarization (inhibitory effect) or
depolarization (stimulatory effect). <sup><xref ref-type="bibr" rid="ref23">23</xref></sup>
Given the multiple genes and the heteromer association in a single
receptor complex this yields to a large repertoire of GABA <sub>A</sub>
receptors with a distribution specific to certain brain areas.
Understanding the receptor distribution is mandatory for the proper evaluation of
the compound effects both in the in vitro and in vivo studies. The effects of
compounds will tend to be determinant in signal transmission at postsynaptic
receptors whereas they will have a more general modulatory activity at extrasynaptic
receptors.  </p>
<p>
Following the determination of a suitable drug target, the design of
the strategic procedure for the primary test can be determined. While expression of
the receptors in a reconstituted system represents a suitable choice, details
regarding the protein origin and sequence must be considered. Special attention must
be paid to the gene species as well as possible alternate splicing and variants. For
example, it is known that two alternate splicing variants are expressed for the GABA
<sub>A</sub>
g2 subunit and that physiological and pharmacological differences are
observed between these two forms. In addition, the role of associated proteins and
their effect should not be neglected. <sup><xref ref-type="bibr" rid="ref24">24</xref></sup>
Furthermore, since the functional outcome of GABA <sub>A</sub>
receptor activation will depend upon the chloride gradient, this
parameter must be kept in mind and studies should be conducted using the appropriate
experimental paradigm. <sup><xref ref-type="bibr" rid="ref23">23</xref></sup>
  </p>
<p>
Recombinant receptor experiments conducted in cell lines or, for
example, Xenopus oocytes, represent one of the possible first steps for testing
compounds. While mammalian cells offer several advantages, different factors might
also influence the outcome of the studies. First, the expression background of the
cell must be appropriately verified, to confirm that they are not expressing the
gene of interest by themselves, and whether there is an influence of related
associated genes. <sup><xref ref-type="bibr" rid="ref25">25</xref></sup>
, <sup><xref ref-type="bibr" rid="ref26">26</xref></sup>
To appropriately mimic the heterozygosity of the human diploid gene
conditions, expression of the mutated and normal gene must be conducted. <sup><xref ref-type="bibr" rid="ref27">27</xref></sup>
, <sup><xref ref-type="bibr" rid="ref28">28</xref></sup>
  </p>
<p>
Considering the multiple genes encoding for a given protein, for
example the GABA <sub>A</sub>
receptors, a typical drug discovery scheme must include suitable
receptor combinations for screening and evaluation against other receptors or
proteins that could cause side effects. In addition, gene splicings or variants must
be evaluated, as must the appropriateness of the animal models that will be used in
the validation and safety testing.  </p>
<p>
The selectivity of small molecules displaying agonistic or antagonistic
properties being developed is often discussed. Development of positive or negative
allosteric modulators that can enhance or reduce the intrinsic activity of the
receptors is receiving special attention. Whereas benzodiazepines represent a
classical example of positive allosteric modulators, other molecules such as
neurosteroids are showing interesting alternatives. <sup><xref ref-type="bibr" rid="ref29">29</xref></sup>
, <sup><xref ref-type="bibr" rid="ref30">30</xref></sup>
The recent success of compounds developed by Sage Therapeutics in the
case of certain forms of epilepsies or postpartum depression illustrates the
advantages of positive allosteric modulators. Negative allosteric modulators
targeted at specific receptor subtypes might also prove beneficial as shown in a
recent study conducted at a5-containing receptors. <sup><xref ref-type="bibr" rid="ref31">31</xref></sup>
  </p>
<p>
Understanding the neuronal networks which contain the target receptor
is the next level of complexity that must be addressed in the animal model. The
receptor composition must be examined as precisely as possible. For example, recent
work conducted in monkeys revealed that benzodiazepines caused a mild form of
sedation mediated by a2/3 containing receptors versus a moderate/deep sedation
caused by a1-containing receptors. <sup><xref ref-type="bibr" rid="ref32">32</xref></sup>
Indications, such as the recently approved brexanolone compound which
is efficacious in postpartum depression and which acts at the extrasynaptic
receptors such as those containing the a4β3d subunits, require a model allowing
differentiation from the compound targeting the a1β2g2 receptors. Information about
the localization of receptors in the different brain areas and furthermore at the
cellular and subcellular level is determinant in understanding the receptor function
in the native network. There too, designing a restricted number of experiments with
the most appropriate model is expected to be greatly beneficial in the development
pathway.  </p>
</sec>
<sec>
<title>How genetics is modifying our thoughts about pharmacology </title>
<p>
Cloning and sequencing of a number of genes encoding for determinant
functions such as voltage or ligand-gated ion channels brought spectacular progress
in biological sciences with, namely, the possibility to selectively express and
probe the properties of a defined set of proteins. The development of sequencing
technology led to the release of the first human genome draft sequence in 2001.
Aimed at determining the sequence of human genes, this initial project took about 15
years to be completed. Enormous progress made both in the sequencing technology and
computer sciences are now allowing the sequence analysis of an entire human genome
in a matter of days. Major projects initiated by the 1000 Genomes Consortium and the
Exome Aggregation Consortium will enable continued discovery of gene variants in
relation to disease phenotypes. Moreover, in parallel, other projects have
developed, including the Exome Sequencing Project or the Exome Aggregation
Consortium.  </p>
<p>
Generation of databases attempting to link a phenotype to a given set
of mutations is, however, hampered by the number of possible mutations associated
within a single gene and the understanding of the corresponding clinical phenotype.
This is well exemplified in the case of genetically transmissible epilepsies such as
autosomal dominant frontal lobe epilepsy (ADNFLE). Identified more than 20 years ago
with the discovery of a first mutation in <italic>CHRNA4</italic>
, the gene that encodes for the neuronal nicotinic acetylcholine
receptor (nAChR), the clinical phenotype associated with this rare disease was
thought to be sufficiently specific to be clinically homogenous. <sup><xref ref-type="bibr" rid="ref33">33</xref></sup>
However, knowing that the major brain nAChRs are hetero-pentamers
composed of α4 and β2 subunits, it was immediately obvious that mutations in
<italic>CHRNB2</italic>
that encodes for the β2 subunit might also be at the origin of the
ADNFLE phenotype. This hypothesis was subsequently confirmed by the characterization
of a newly identified mutation in <italic>CHNRB2</italic>
. <sup><xref ref-type="bibr" rid="ref34">34</xref></sup>
, <sup><xref ref-type="bibr" rid="ref35">35</xref></sup>
Since these initial descriptions, several mutations have been
identified in <italic>CHRNA4</italic>
and <italic>CHNRB2</italic>
, confirming the association between the ADNFLE clinical phenotype and
genotype. Importantly, patients suffering from ADNFLE are heterozygous for
<italic>CHRNA4</italic>
or <italic>CHNRB2</italic>
indicating that the mutation must have a dominant effect. In vitro
experiments conducted in different expression systems including recordings in
<italic>Xenopus</italic>
oocytes or transfected mammalian cells revealed that the mutations are
causing multiple effects with differences associated with the specificity of the
modified amino acids but that overall, they all caused an increase in the
sensitivity to the natural ligand (acetylcholine). <sup><xref ref-type="bibr" rid="ref28">28</xref></sup>
, <sup><xref ref-type="bibr" rid="ref36">36</xref></sup>
  </p>
<p>
Introduction of these mutations in mouse or rat models offered
additional information about the role of nAChRs in brain function and the
association with a genetically transmissible epilepsy (reviewed in refs 37,38). When
introduced in mice, <italic>CHNRA4</italic>
mutation a4-S248F replicated some forms of epilepsies, but only in a
mouse with a particular background. <sup><xref ref-type="bibr" rid="ref37">37</xref></sup>
This indicates that mutation of <italic>CHRNA4</italic>
is probably insufficient to cause epilepsies but that additional
factors are necessary, and this could explain the low penetrance of the clinical
phenotype and detection of healthy obligatory carriers.  </p>
<p>
To date, carbamazepine remains the best treatment for ADNFLE but was
shown to be efficacious only for certain mutations and, moreover,
pharmaco-resistance observed in the clinic was documented underlying the role of
brain plasticity in long-term treatment in humans. Another important lesson learned
from the ADNFLE studies concerns the complexity of the clinical phenotype. While
nocturnal epileptic episodes are unambiguous manifestations of the disease,
additional factors must also be considered. Namely, while mutations in the
<italic>CHRNA4</italic>
gene are affecting only a4- and β2-containing receptors, alterations
in the coding sequence of the accessory β2 subunit are expected to affect additional
receptor subtypes such as a2β2 which is highly expressed in the frontal cortex. It
is therefore not surprising to observe that <italic>CHRNB2</italic>
mutations are probably associated with cognitive impairment. <sup><xref ref-type="bibr" rid="ref29">29</xref></sup>
Further development in the genetic analysis and correlation with
clinical phenotype pointed to mutations in <italic>CHRNA2</italic>
<sup><xref ref-type="bibr" rid="ref38">38</xref></sup>
and, surprisingly, in the sodium, activated potassium channel (Slack)
<italic>KCNT1</italic>
. <sup><xref ref-type="bibr" rid="ref39">39</xref></sup>
  </p>
<p>
As progress is made in the identification of genetic variants and the
possible link with protein function, characterization of the possible alteration of
the protein function and understanding of the overall cellular and network circuit
physiology and pharmacology becomes a key pointer towards the development of novel
molecules.  </p>
</sec>
<sec>
<title>Common gene variants and complex  disorders </title>
<p>
Based on genetic approaches, one tendency is to focus attention on a
single gene and conclude that presence or absence of a given variant will determine
the overall phenotype. Whereas such an association exists in strongly correlated
genetic variants, these remain rare cases illustrating the specificity of a given
gene. However, the observation of an obligatory carrier in which the mutation is
known to be present but not expressed clinically illustrates that in many cases the
penetrance of the disease is incomplete. In other words, this suggests that presence
of a given mutation can be the cause of a given disease but that it can be
compensated for by other factors preventing the apparition of the clinical
phenotype.   </p>
<p>
In a most recent study reported for a large cohort of 6987 children
affected by global developmental delay and autism that were characterized both
clinically and genetically, it was shown that 7.7% of the variance in risk was
attributable to common genetic variations. <sup><xref ref-type="bibr" rid="ref40">40</xref></sup>
Moreover, this was further confirmed in an independent sample of 728
families from the same cohort in which a child and parents were analyzed; this
revealed that the neurodevelopmental disorder is transmitted from the parents. In
addition, the common-variant signal was significantly correlated with lower
educational achievement and risk of schizophrenia.  </p>
<p>
These findings were further analyzed in the light of previous studies
in which correlation between autism and other parameters such as height, birth
weight, or cranial volume were examined and it was concluded that patients with
monogenic disorders are affected by variants found in the general population.
Altogether, these studies highlight the need for broader genetic screening and
analysis of multiple variants that will account for a given clinical phenotype.  </p>
<p>
Analysis of the haplotype variations versus their pair diplotypes
conducted in European population samples unveiled an immense diversity. On average,
this corresponded to about 235 forms per gene with less than 15% having an autosomal
dominant predominance. <sup><xref ref-type="bibr" rid="ref41">41</xref></sup>
Examples of genetic variants and the relevance of their analysis in
drug treatment was already documented for cardiovascular treatment with the
anticoagulant warfarin, and its resistance in specific patients, or the
reduction-of-function variants in <italic>CYP2C</italic>
<sup><xref ref-type="bibr" rid="ref19">19</xref></sup>
, the enzyme responsible for the bioactivation of antiplatelet
medication (clopidogrel). <sup><xref ref-type="bibr" rid="ref42">42</xref></sup>
The importance of gene variation in drug-related genes was further
highlighted in another study suggesting the need for a closer examination both in
clinical trials and day-to-day practice. <sup><xref ref-type="bibr" rid="ref43">43</xref></sup>
  </p>
<p>
The most recent pharmacogenomic analysis of GPCR drug targets conducted
on data analyses from about 70 000 individuals revealed that genetic variations of
the m-opiod and cholecystokinin-A receptors could lead to altered or adverse drug
response. Whereas the combination of multiple genetic variants might be complex to
recapitulate in expression systems or animal models, it can be foreseen that
analysis of the different key elements will lead to a better comprehension of the
disease.  </p>
</sec>
<sec>
<title>Translation from recombinant receptors to  a functional network </title>
<p>
Understanding the neuronal networks in which the target receptor is
involved is the next level of complexity that must be addressed. The precise
receptor composition must be examined as illustrated by the recent work conducted in
animal experiments, which revealed a mild form of sedation mediated by the GABA
<sub>A</sub>
receptors containing a2/3 GABA <sub>A</sub>
subunits versus a moderate/deep sedation caused by a1
subunit-containing receptors. <sup><xref ref-type="bibr" rid="ref32">32</xref></sup>
Similarly, symptoms thought to be associated with extrasynaptic
receptors such as those containing the a4β3d subunits require a model that differs
from the compound targeting the a1β2g2 subunit containing receptors. Information
about the localization of the receptors in function of the brain areas and
furthermore at the cellular and subcellular level is determinant to address the
receptor role in the native network. There too, designing restricted numbers of
experiments with the most appropriate model is expected to be greatly beneficial in
the development pathway.  </p>
<p>
The outcome of modulating these molecular targets will be changes to
the electrical signaling which underpins brain activity. Using electrophysiological
approaches, it is possible to assess these changes from activity at the level of a
single protein, through to measurements of synchronized activity between brain
regions. In particular, it may be that developments in our ability to measure
activity at the network level will benefit future neuroscience drug discovery. In
patients, this activity can be measured noninvasively with electrodes applied to the
scalp to record an electroencephalogram (EEG) or by magnetoencephalography (MEG).
The EEG represents ensemble activity of neurons in the cortex, which in turn are
being modulated by deeper brain structures. Such recordings revealed that the brain
is highly synchronized into defined rhythms, or oscillations, at frequencies ranging
from a few Hz to over 100 Hz, and these different rhythms are tightly linked to
specific activities. These oscillations are thought to ensure coordination of
neuronal activity both within defined structures, and across different brain
regions. This synchrony is vital for cognitive function and for neurophysiological
processes such as synaptic plasticity, which is essential for formation of new
memories. <sup><xref ref-type="bibr" rid="ref44">44</xref></sup>
The EEG, and other techniques such as functional magnetic resonance
imaging, have demonstrated that in CNS disorders the synchronized activity is
disrupted. <sup><xref ref-type="bibr" rid="ref45">45</xref></sup>
- <sup><xref ref-type="bibr" rid="ref47">47</xref></sup>
  </p>
<p>
That reproducible disruptions in electrical signaling that can be
measured in patients raises the prospect of development of functional biomarkers. It
was recently reported that clinical trials making use of biomarkers in patient
selection <sup><xref ref-type="bibr" rid="ref48">48</xref></sup>
had higher overall success probabilities than trials without
biomarkers. This data set was across a range of trials, so not limited to CNS, and
the situation was less clear for trials using biomarkers as a measure of the test
compound’s efficacy, but it does suggest that development of biomarkers is
important.   </p>
<p>
The use of measures such as the EEG in clinical trials may be
particularly attractive as the neuronal oscillations recorded in humans are also
present across species, and may be reproduced in preparations such as the in vitro
brain slice. <sup><xref ref-type="bibr" rid="ref49">49</xref></sup>
, <sup><xref ref-type="bibr" rid="ref50">50</xref></sup>
As such the measurement of neuronal oscillations may provide a route
for translational models for many CNS disorders.  </p>
<p>
The in vitro brain slice preparation provides a valuable preparation
for the study of neuronal physiology: the synaptic connections that occur in vivo
are maintained in the slice, neurones can easily be identified and accessed for
recording, the external environment can easily be manipulated, and drugs can be
applied and removed quickly. <sup><xref ref-type="bibr" rid="ref51">51</xref></sup>
This approach has been invaluable in research into neurophysiological
processes, such as learning and memory, and the cellular activity that generates
neuronal oscillations.  </p>
<p>
Brain slices prepared containing a region of interest, such as the
hippocampus or prefrontal cortex, may be used to demonstrate that target engagement
from a primary screen translates to the native target. This can be to study the
effects on synaptic transmission, through to studying more complex network activity
as illustrated in <italic>Figure 1</italic>
. Here, gamma frequency oscillations are recorded in the CA3 region of
the hippocampus. In addition to the potential translatability, these neuronal
oscillations are particularly attractive for pharmacological studies as they require
a fully functioning neuronal network, with the inhibitory systems intact, and the
signal is stable for hours allowing application of compounds over a concentration
range on the same slice, or application of different compounds. <sup><xref ref-type="bibr" rid="ref52">52</xref></sup>
, <sup><xref ref-type="bibr" rid="ref53">53</xref></sup>
In <italic>Figure 1</italic>
the actions on the oscillations of amphetamine and guanfacine are
illustrated. These are drugs that are known to modulate cognitive performance in
animals and humans, albeit via different mechanisms, and have been used to treat
conditions such as attention deficit-hyperactivity disorder (ADHD). Amphetamine is
thought to exert its effects (at least in part) via dopaminergic mechanisms, whereas
guanfacine is an a2A- adrenoceptor agonist. The data in <italic>Figure 1</italic>
illustrate that both of these compounds modulate hippocampal circuit
function, but in differing ways. Fully investigating the effects of putative
medicines on neuronal function at the network level may be valuable in providing a
functional signature to particular molecular targets.  </p>
<p>
Much of the preclinical electrophysiology, both in vitro and in vivo,
has been conducted with single electrodes; however, in recent years technologies
have been developed that allow recording from multiple sites, both in vitro, and in
vivo. <sup><xref ref-type="bibr" rid="ref54">54</xref></sup>
These approaches generate massive data sets that not only allow study
of the network activity, but simultaneously sample the activity of the individual
neurones underlying this activity. Through application of spike-sorting algorithms,
it is possible to separate the recording data into streams from specific cell types
and demonstrate how the activity of individual cells correlates with the overall
network activity. In combination with other technologies, such as optogenetics. <sup><xref ref-type="bibr" rid="ref55">55</xref></sup>
- <sup><xref ref-type="bibr" rid="ref57">57</xref></sup>
These approaches will be of great value to neuroscience drug
discovery. Application of these approaches will allow in-depth knowledge of the
actions of different compounds on neuronal function, of relevance both for how a
compound may control the disease, and also to aid understanding of side effects.  </p>
<p>
A further development that may aid generation of more predictive data
is the recording of electrical signaling from human neuronal tissue <sup><xref ref-type="bibr" rid="ref58">58</xref></sup>
: it is possible to prepare brain slices from tissue removed from
patients undergoing elective neurosurgery. As with tissue from rodents, the human
brain slices allow study of compound effects at the cellular and network level. Of
course, these tissues come from patients who will be medicated and have an ongoing
medical condition, so use of the tissue may not be applicable to all CNS disorders,
but for conditions such as epilepsy it is possible to reproduce the network activity
that underlies the patient’s conditions in vitro. These approaches will facilitate a
greater understanding of the condition and may be valuable in the evaluation of new
treatments.  </p>
<p>
Addition of D-amphetamine to the bathing medium (10μM) resulted in
changes in the power spectrum recorded in a rodent brain slice, such that there was
an overall increase in power and the peak in the spectrum shifted from the gamma
range to the 10-20 Hz (“beta”) range. This was associated with the occurrence of
high-amplitude sharp wave activity. Addition of guanfacine (10μM) to the bathing
medium had little effect on the peak frequency in the power spectrum, but decreased
the gamma-frequency power to 66% of control.  </p>
</sec>
<sec>
<title>Conclusions </title>
<p>
Rationalization in drug development has become a mantra in large
pharmaceutical companies, and it is often thought that it is more efficient to
collaborate with (and even in given cases to acquire) smaller biotechnology
companies presenting an adequate potential rather than establishing in-house a
complete development process. Cuts in internal research work forces have been
observed in many companies while small biotechnology companies are burgeoning. The
lack in internal resources of small biotechnology companies and reduced forces in
larger groups has favored the development of specialized CROs. To be successful,
CROs need to produce high-quality science while maintaining technologies and
internal knowledge at the forefront of the scientific research.  </p>
<p>
Progress made in genetics combined with deeper analysis of brain
circuits has shown the need for highly specialized scientists that can contribute in
appropriate groups to exploring and understanding the effects of compounds in the
brain at the highest level. Analysis of drug effects range from the molecular to the
neural circuit level, including the potential influence of genetic variants. In view
of these multiple requirements in drug discovery, and the need for highly
specialized skilled scientists and specific equipment at each step of drug
development, the collaboration between pharmaceutical companies and CROs will
probably grow stronger. This can make a significant contribution to minimizing time
and cost of the development of new therapies.  </p>
<sec>
<title>Modulation of gamma oscillations by drugs used in ADHD.</title>
<fig id="d35e565" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<title>Modulation of gamma oscillations by drugs used in ADHD.</title>
</caption>
<graphic xlink:href="DCNS_21.2_fig1_Bertrand"></graphic>
</fig>
</sec>
</sec>
</body>
<back>
<ack>
<p>The authors have no conflicts of interest to declare.</p>
</ack>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<article-title>Global analysis of neurological disease: burden and
benefit.</article-title>
<source/>
<italic>Lancet Neurol.</italic>
<year>2017</year>
<pub-id pub-id-type="doi">10.1016/S1474-4422(17)30338-1.</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dykxhoorn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Magnusson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dalman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kirkbride</surname>
<given-names>JB.</given-names>
</name>
</person-group>
<article-title>Risk of schizophrenia, schizoaffective, and bipolar disorders by
migrant status, region of origin, and age-at-migration: A national cohort
study of 1.8 million people.</article-title>
<source/>
<italic>Psychol Med.</italic>
<year>2018</year>
<volume>5</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291718003227.[Epubaheadofprint].</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Möhler</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Endogenous benzodiazepine site peptide ligands operating
bidirectionally in vivo in neurogenesis and thalamic
oscillations.</article-title>
<source/>
<italic>Neurochem Res.</italic>
<year>2014</year>
<volume>39</volume>
<issue>6</issue>
<fpage>1032</fpage>
<lpage>1036</lpage>
<pub-id pub-id-type="pmid">24715673</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ban</surname>
<given-names>TA.</given-names>
</name>
</person-group>
<article-title>Fifty years of chlorpromazine: A historical
perspective.</article-title>
<source/>
<italic>Neuropsychiatr Dis Treat.</italic>
<year>2007</year>
<volume>3</volume>
<issue>4</issue>
<fpage>495</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="pmid">19300578</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seeman</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Dopamine D2 receptors as treatment targets in
schizophrenia.</article-title>
<source/>
<italic>Clin Schizophr Relat Psychoses.</italic>
<year>2010</year>
<volume>4</volume>
<issue>1</issue>
<fpage>56</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">20643630</pub-id>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mailman</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Murthy</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Third generation antipsychotic drugs: Partial agonism or receptor
functional selectivity?</article-title>
<source/>
<italic>Curr Pharm Des.</italic>
<year>2010</year>
<volume>16</volume>
<issue>5</issue>
<fpage>488</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="pmid">19909227</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashoor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lorke</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nurulain</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Effects of phenothiazine-class antipsychotics on the function of
α7-nicotinic acetylcholine receptors.</article-title>
<source/>
<italic>Eur J Pharmacol.</italic>
<year>2011</year>
<volume>673</volume>
<issue>1-3</issue>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">22044918</pub-id>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giraudat</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heidmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Changeux</surname>
<given-names>JP.</given-names>
</name>
</person-group>
<article-title>Structure of the high-affinity binding site for noncompetitive
blockers of the acetylcholine receptor: Serine-262 of the delta subunit is
labeled by [3H]chlorpromazine.</article-title>
<source/>
<italic>Proc Natl Acad Sci U S A.</italic>
<year>1986</year>
<volume>83</volume>
<issue>8</issue>
<fpage>2719</fpage>
<lpage>2723</lpage>
<pub-id pub-id-type="pmid">3085104</pub-id>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grinevich</surname>
<given-names>VP</given-names>
</name>
<name>
<surname>Papke</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Lippiello</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Bencherif</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Atypical antipsychotics as noncompetitive inhibitors of
alpha4beta2 and alpha7 neuronal nicotinic receptors.</article-title>
<source/>
<italic>Neuropharmacology.</italic>
<year>2009</year>
<volume>57</volume>
<issue>2</issue>
<fpage>183</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="pmid">19481556</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barygin</surname>
<given-names>OI</given-names>
</name>
<name>
<surname>Nagaeva</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Tikhonov</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Belinskaya</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Vanchakova</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Shestakova</surname>
<given-names>NN.</given-names>
</name>
</person-group>
<article-title>Inhibition of the NMDA and AMPA receptor channels by
antidepressants and antipsychotics.</article-title>
<source/>
<italic>Brain Res.</italic>
<volume>2017</volume>
<issue>1660</issue>
<fpage>58</fpage>
<lpage>66</lpage>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Novellis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Paolone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Olanzapine, but not clozapine, increases glutamate release in the
prefrontal cortex of freely moving mice by inhibiting d-aspartate oxidase
activity.</article-title>
<source/>
<italic>Sci Rep.</italic>
<year>2017</year>
<volume>7</volume>
<fpage>46288</fpage>
<pub-id pub-id-type="pmid">28393897</pub-id>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moser</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>McNaughton</surname>
<given-names>BL.</given-names>
</name>
</person-group>
<article-title>Spatial representation in the hippocampal formation: A
history.</article-title>
<source/>
<italic>Nat Neurosci.</italic>
<year>2017</year>
<volume>20</volume>
<issue>11</issue>
<fpage>1448</fpage>
<lpage>1464</lpage>
<pub-id pub-id-type="pmid">29073644</pub-id>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayward</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Adamson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Neill</surname>
<given-names>JC.</given-names>
</name>
</person-group>
<article-title>Partial agonism at the α7 nicotinic acetylcholine receptor
improves attention, impulsive action and vigilance in low attentive
rats.</article-title>
<source/>
<italic>Eur Neuropsychopharmacol.</italic>
<year>2017</year>
<volume>4</volume>
<fpage>325</fpage>
<lpage>335</lpage>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keefe</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Dgetluck</surname>
<given-names>N</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Randomized, double-blind, placebo-controlled study of
encenicline, an alpha-7 nicotinic acetylcholine receptor agonist as a
treatment for cognitive impairment in schizophrenia.</article-title>
<source/>
<italic>Neuropsychopharmacology.</italic>
<year>2015</year>
<volume>40</volume>
<issue>13</issue>
<fpage>3053</fpage>
<lpage>3060</lpage>
<pub-id pub-id-type="pmid">26089183</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoiljkovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leventhal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen </surname>
<given-names>A</given-names>
</name>
<name>
<surname>et al. </surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Concentration-response relationship of the α7 nicotinic
acetylcholine receptor agonist FRM-17874 across multiple in vitro and in
vivo assays.</article-title>
<source/>
<italic>Biochem Pharmacol.</italic>
<year>2015</year>
<volume>97</volume>
<issue>4</issue>
<fpage>579</fpage>
<lpage>589</lpage>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rollema</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Nicotinic agonists and antagonists. In: </article-title>
<source/>
<italic>Encyclopedia of Psychopharmacology.</italic>
<year>2014</year>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Lindemann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jønch</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Drug development for neurodevelopmental disorders: Lessons
learned from fragile X syndrome.</article-title>
<source/>
<italic>Nat Rev Drug Discov.</italic>
<year>2018</year>
<volume>17</volume>
<issue>4</issue>
<fpage>280</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">29217836</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bierut</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Stitzel</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Variants in nicotinic receptors and risk for nicotine
dependence.</article-title>
<source/>
<italic>Am J Psychiatry.</italic>
<year>2008</year>
<volume>165</volume>
<issue>9</issue>
<fpage>1163</fpage>
<lpage>1171</lpage>
<pub-id pub-id-type="pmid">18519524</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haller</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Budde</surname>
<given-names>J</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Rare missense variants in CHRNB3 and CHRNA3 are associated with
risk of alcohol and cocaine dependence.</article-title>
<source/>
<italic>Hum Mol Genet.</italic>
<year>2013</year>
<volume>23</volume>
<issue>3</issue>
<fpage>810</fpage>
<lpage>819</lpage>
<pub-id pub-id-type="pmid">24057674</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Alachkar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Nicotinic alpha5 receptor subunit mrna expression is associated
with distant 5’ upstream polymorphisms.</article-title>
<source/>
<italic>Eur J Hum Genet.</italic>
<year>2010</year>
<volume>19</volume>
<issue>1</issue>
<fpage>76</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">20700147</pub-id>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bierut</surname>
<given-names>LJ.</given-names>
</name>
</person-group>
<article-title>Convergence of genetic findings for nicotine dependence and
smoking related diseases with chromosome 15q24-25.</article-title>
<source/>
<italic>Trends Pharmacol Sci.</italic>
<year>2010</year>
<volume>31</volume>
<issue>1</issue>
<fpage>46</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">19896728</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>RL.</given-names>
</name>
</person-group>
<article-title>Molecular pathogenic basis for GABRG2 mutations associated with a
spectrum of epilepsy syndromes, from generalized absence epilepsy to dravet
syndrome.</article-title>
<source/>
<italic>JAMA Neurol.</italic>
<year>2016</year>
<volume>73</volume>
<issue>8</issue>
<fpage>1009</fpage>
<lpage>1016</lpage>
<pub-id pub-id-type="pmid">27367160</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knoflach</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>GABAA receptor-mediated neurotransmission: Not so simple after
all.</article-title>
<source/>
<italic>Biochem Pharmacol.</italic>
<year>2016</year>
<volume>115</volume>
<fpage>10</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">27002180</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maher</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Matta</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seierstad</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bredt </surname>
<given-names>DS.</given-names>
</name>
</person-group>
<article-title>Getting a handle on neuropharmacology by targeting
receptor-associated proteins.</article-title>
<source/>
<italic>Neuron.</italic>
<year>2017</year>
<volume>96</volume>
<issue>5</issue>
<fpage>989</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="pmid">29216460</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matta</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Davini</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Siuda </surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Bredt</surname>
<given-names>DS.</given-names>
</name>
</person-group>
<article-title>NACHO mediates nicotinic acetylcholine receptor function
throughout the brain.</article-title>
<source/>
<italic>Cell Rep.</italic>
<year>2017</year>
<volume>19</volume>
<issue>4</issue>
<fpage>688</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="pmid">28445721</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matta</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Davini</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Bredt</surname>
<given-names>DS.</given-names>
</name>
</person-group>
<article-title>Brain α7 nicotinic acetylcholine receptor assembly requires
NACHO.</article-title>
<source/>
<italic>Neuron.</italic>
<year>2016</year>
<volume>89</volume>
<issue>5</issue>
<fpage>948</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="pmid">26875622</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Terry</surname>
<given-names>AV.</given-names>
</name>
</person-group>
<article-title>The wonderland of neuronal nicotinic acetylcholine
receptors.</article-title>
<source/>
<italic>Biochem Pharmacol.</italic>
<year>2017</year>
<volume>151</volume>
<fpage>214</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">29248596</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinlein</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Hoda</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bertrand </surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Mutations in familial nocturnal frontal lobe epilepsy might be
associated with distinct neurological phenotypes.</article-title>
<source/>
<italic>Seizure.</italic>
<year>2012</year>
<volume>21</volume>
<issue>2</issue>
<fpage>118</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="pmid">22036597</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carver</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>DS.</given-names>
</name>
</person-group>
<article-title>Neurosteroid structure-activity relationships for functional
activation of extrasynaptic δgabaa receptors.</article-title>
<source/>
<italic>J Pharmacol Exp Ther.</italic>
<year>2016</year>
<volume>357</volume>
<issue>1</issue>
<fpage>188</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">26857959</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seljeset</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Laverty</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Smart</surname>
<given-names>TG.</given-names>
</name>
</person-group>
<article-title>Inhibitory neurosteroids and the GABAA receptor.</article-title>
<source/>
<italic>Adv Pharmacol.</italic>
<year>2015</year>
<volume>72</volume>
<fpage>165</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="pmid">25600370</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawaharada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>ONO-8590580, a novel gabaaα5 negative allosteric modulator
enhances long-term potentiation and improves cognitive deficits in
preclinical models.</article-title>
<source/>
<italic>J Pharmacol Exp Ther.</italic>
<year>2018</year>
<volume>366</volume>
<issue>1</issue>
<fpage>58</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">29674331</pub-id>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duke</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Evidence that sedative effects of benzodiazepines involve
unexpected gabaareceptor subtypes: Quantitative observation studies in
rhesus monkeys.</article-title>
<source/>
<italic>J Pharmacol Exp Ther.</italic>
<year>2018</year>
<volume>366</volume>
<issue>1</issue>
<fpage>145</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">29720564</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinlein</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Mulley</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Propping</surname>
<given-names>P</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>A missense mutation in the neuronal nicotinic acetylcholine
receptor alpha 4 subunit is associated with autosomal dominant nocturnal
frontal lobe epilepsy.</article-title>
<source/>
<italic>Nat Genet.</italic>
<year>1995</year>
<volume>11</volume>
<issue>2</issue>
<fpage>201</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="pmid">7550350</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Fusco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Becchetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Patrignani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>The nicotinic receptor beta 2 subunit is mutant in nocturnal
frontal lobe epilepsy.</article-title>
<source/>
<italic>Nat Genet.</italic>
<year>2000</year>
<volume>26</volume>
<issue>3</issue>
<fpage>275</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">11062464</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Favre</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>M</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>CHRNB2 is the second acetylcholine receptor subunit associated
with autosomal dominant nocturnal frontal lobe epilepsy.</article-title>
<source/>
<italic>Am J Hum Genet.</italic>
<year>2001</year>
<volume>68</volume>
<issue>1</issue>
<fpage>225</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="pmid">11104662</pub-id>
</element-citation>
</ref>
<ref id="ref36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eggert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Winterer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wanischeck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hoda </surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Steinlein</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>The nicotinic acetylcholine receptor alpha 4 subunit contains a
functionally relevant SNP haplotype.</article-title>
<source/>
<italic>BMC Genet.</italic>
<year>2015</year>
<volume>16</volume>
<fpage>46</fpage>
<pub-id pub-id-type="pmid">25934188</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boillot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baulac</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Genetic models of focal epilepsies.</article-title>
<source/>
<italic>J Neurosci Methods.</italic>
<year>2016</year>
<volume>260</volume>
<fpage>132</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="pmid">26072248</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becchetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aracri</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Meneghini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brusco </surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amadeo</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The role of nicotinic acetylcholine receptors in autosomal
dominant nocturnal frontal lobe epilepsy.</article-title>
<source/>
<italic>Front Physiol.</italic>
<year>2015</year>
<volume>6</volume>
<fpage>22</fpage>
<pub-id pub-id-type="pmid">25717303</pub-id>
</element-citation>
</ref>
<ref id="ref39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Kronengold</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barcia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Human slack potassium channel mutations increase positive
cooperativity between individual channels.</article-title>
<source/>
<italic>Cell Rep.</italic>
<year>2014</year>
<volume>9</volume>
<issue>5</issue>
<fpage>1661</fpage>
<lpage>1672</lpage>
<pub-id pub-id-type="pmid">25482562</pub-id>
</element-citation>
</ref>
<ref id="ref40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niemi</surname>
<given-names>MEK</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Common genetic variants contribute to risk of rare severe
neurodevelopmental disorders.</article-title>
<source/>
<italic>Nature.</italic>
<year>2018</year>
<volume>562</volume>
<issue>7726</issue>
<fpage>268</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="pmid">30258228</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoehe</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Lehrach</surname>
<given-names>H</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Multiple haplotype-resolved genomes reveal population patterns of
gene and protein diplotypes.</article-title>
<source/>
<italic>Nat Commun.</italic>
<year>2014</year>
<volume>5</volume>
<fpage>5569</fpage>
<pub-id pub-id-type="pmid">25424553</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roden</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Wilke</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>CM.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics: The genetics of variable drug
responses.</article-title>
<source/>
<italic>Circulation.</italic>
<year>2011</year>
<volume>123</volume>
<issue>15</issue>
<fpage>1661</fpage>
<lpage>1670</lpage>
<pub-id pub-id-type="pmid">21502584</pub-id>
</element-citation>
</ref>
<ref id="ref43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schärfe</surname>
<given-names>CPI</given-names>
</name>
<name>
<surname>Tremmel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kohlbacher</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>DS.</given-names>
</name>
</person-group>
<article-title>Genetic variation in human drug-related genes.</article-title>
<source/>
<italic>Genome Med.</italic>
<year>2017</year>
<volume>9</volume>
<issue>1</issue>
<fpage>117</fpage>
<pub-id pub-id-type="pmid">29273096</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latchoumane</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Ngo</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Born</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HS.</given-names>
</name>
</person-group>
<article-title>Thalamic spindles promote memory formation during sleep through
triple phase-locking of cortical, thalamic, and hippocampal
rhythms.</article-title>
<source/>
<italic>Neuron.</italic>
<year>2017</year>
<volume>95</volume>
<issue>2</issue>
<fpage>424</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="pmid">28689981</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-Sanz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bruña</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Garcés</surname>
<given-names>P</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Functional connectivity disruption in subjective cognitive
decline and mild cognitive impairment:  A common pattern of
alterations.</article-title>
<source/>
<italic>Front Aging  Neurosci.</italic>
<year>2017</year>
<volume>9</volume>
<fpage>109</fpage>
<pub-id pub-id-type="pmid">28484387</pub-id>
</element-citation>
</ref>
<ref id="ref46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nimmrich</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Draguhn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Axmacher</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Neuronal network oscillations in neurodegenerative
diseases.</article-title>
<source/>
<italic>Neuromolecular Med.</italic>
<year>2015</year>
<volume>17</volume>
<issue>3</issue>
<fpage>270</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="pmid">25920466</pub-id>
</element-citation>
</ref>
<ref id="ref47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grent-’t-Jong</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goense</surname>
<given-names>J</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Resting-state gamma-band power alterations in schizophrenia
reveal E/i-balance abnormalities across illness-stages.</article-title>
<source/>
<italic>Elife.</italic>
<year>2018</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.7554/eLife.37799.</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Siah</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>AW.</given-names>
</name>
</person-group>
<article-title>Estimation of clinical trial success rates and related
parameters.</article-title>
<source/>
<italic>Biostatistics.</italic>
<year>2018</year>
<volume>20</volume>
<issue>2</issue>
<fpage>273</fpage>
<lpage>286</lpage>
</element-citation>
</ref>
<ref id="ref49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huberfeld</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Blauwblomme</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miles</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Hippocampus and epilepsy: Findings from human
tissues.</article-title>
<source/>
<italic>Rev Neurol (Paris).</italic>
<year>2015</year>
<volume>171</volume>
<issue>3</issue>
<fpage>236</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">25724711</pub-id>
</element-citation>
</ref>
<ref id="ref50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazelot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Teleńczuk</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Miles</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Single CA3 pyramidal cells trigger sharp waves in vitro by
exciting interneurones.</article-title>
<source/>
<italic>J Physiol.</italic>
<year>2016</year>
<volume>594</volume>
<issue>10</issue>
<fpage>2565</fpage>
<lpage>2577</lpage>
<pub-id pub-id-type="pmid">26728572</pub-id>
</element-citation>
</ref>
<ref id="ref51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crepel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dhanjal</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Garthwaite</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Morphological and electrophysiological characteristics of rat
cerebellar slices maintained in vitro.</article-title>
<source/>
<italic>J Physiol.</italic>
<year>1981</year>
<volume>316</volume>
<fpage>127</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="pmid">7320859</pub-id>
</element-citation>
</ref>
<ref id="ref52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sathyasaikumar</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Tararina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HQ</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Xanthurenic acid formation from 3-hydroxykynurenine in the
mammalian brain: Neurochemical characterization and physiological
effects.</article-title>
<source/>
<italic>Neuroscience.</italic>
<year>2017</year>
<volume>367</volume>
<fpage>85</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">29031603</pub-id>
</element-citation>
</ref>
<ref id="ref53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sathyasaikumar</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Stachowski</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Wonodi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Impaired kynurenine pathway metabolism in the prefrontal cortex
of individuals with schizophrenia.</article-title>
<source/>
<italic>Schizophr Bull.</italic>
<year>2011</year>
<volume>37</volume>
<issue>6</issue>
<fpage>1147</fpage>
<lpage>1156</lpage>
<pub-id pub-id-type="pmid">21036897</pub-id>
</element-citation>
</ref>
<ref id="ref54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buzsáki</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tingley</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Space and time: The hippocampus as a sequence
generator.</article-title>
<source/>
<italic>Trends Cogn Sci.</italic>
<year>2018</year>
<volume>22</volume>
<issue>10</issue>
<fpage>853</fpage>
<lpage>869</lpage>
<pub-id pub-id-type="pmid">30266146</pub-id>
</element-citation>
</ref>
<ref id="ref55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magnin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Francavilla</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Amalyan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Input-specific synaptic location and function of the alpha5 GABAA
receptor subunit in the mouse CA1 hippocampal neurons.</article-title>
<source/>
<italic>J Neurosci.</italic>
<year>2018</year>
<volume>39</volume>
<issue>5</issue>
<fpage>788</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="pmid">30523065</pub-id>
</element-citation>
</ref>
<ref id="ref56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendrela</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K</given-names>
</name>
<name>
<surname>English</surname>
<given-names>D</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>A high-resolution opto-electrophysiology system with a miniature
integrated headstage.</article-title>
<source/>
<italic>IEEE Trans Biomed Circuits Syst.</italic>
<year>2018</year>
<volume>16</volume>
<pub-id pub-id-type="doi">10.1109/TBCAS.2018.2852267.</pub-id>
</element-citation>
</ref>
<ref id="ref57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Weir</surname>
<given-names>RFF.</given-names>
</name>
</person-group>
<article-title>On the development of optical peripheral nerve
interfaces.</article-title>
<source/>
<italic>Neural Regen Res.</italic>
<year>2019</year>
<volume>14</volume>
<issue>3</issue>
<fpage>425</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="pmid">30539808</pub-id>
</element-citation>
</ref>
<ref id="ref58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connor</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Firmin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>McCaughey-Chapman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Monk</surname>
<given-names>R</given-names>
</name>
<name>
<surname>et al.</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Conversion of adult human fibroblasts into neural precursor cells
using chemically modified mrna.</article-title>
<source/>
<italic>Heliyon.</italic>
<year>2018</year>
<volume>4</volume>
<issue>11</issue>
<fpage>e00918</fpage>
<pub-id pub-id-type="pmid">30450440</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>